Seres Therapeutics announced on March 02 2026 that Richard N. Kender will serve as Executive Chair and Interim Chief Executive Officer. Kender, a veteran of the biopharma industry, has been a Seres board member since 2014 and brings more than 35 years of experience in business development and corporate licensing, most recently at Merck & Co. The company’s co‑CEOs, Tom DesRosier and Marella Thorell, will continue in their roles as Chief Legal Officer and Chief Financial Officer, respectively.
The appointment follows Seres’ strategic shift toward advancing its live biotherapeutic programs in inflammatory and immune diseases, with a focus on inflammatory bowel disease and immune‑checkpoint‑related enterocolitis. Management highlighted that Kender’s background in licensing and partnership development is intended to accelerate the company’s efforts to secure external support for its Phase 2 program, SER‑155, and to broaden the platform’s application to other indications.
Kender’s arrival is expected to strengthen Seres’ ability to navigate the company’s current funding challenges and to position the firm for potential collaborations or capital raises as it seeks to sustain operations beyond the projected cash runway into the second quarter of 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.